Sitagliptin is indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Sitaglit is indicated as monotherapy and also indicated for use in combination with metformin, sulfonylurea or thiazolidinediones when diet and exercise plus the single agent does not result in adequate glycemic control.